Karyopharm Therapeutics Azioni (NASDAQ: KPTI)

Ultime notizie per Karyopharm Therapeutics (NASDAQ:KPTI) Azioni

KARYOPHARM THERAPEUTICS INC

Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics Inc

Earnings

ACHC

ACHR

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARCT

ARWR

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CHRS

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FGEN

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HBIO

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LSEA

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVIS

MVST

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

<h3>Gainers</h3>
<ul>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares increased by 98.3% to $4.62 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.4 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock moved upwards by 25.91% to $0.29. The market value of their outstanding shares is at $18.3 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 24.78% to $3.85. The company's market cap stands at $2.0 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares rose 22.62% to $8.4. The market value of their outstanding shares is at $53.7 million. </li>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) stock rose 21.28% to $3.77. The company's market cap stands at $228.3 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 17.11% to $2.19. The company's market cap stands at $3.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Serina Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SER#AMEX">SER</a>) stock fell 21.6% to $4.31 during Wednesday's pre-market session. The company's market cap stands at $42.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock declined by 17.37% to $2.38. The market value of their outstanding shares is at $22.4 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares decreased by 16.39% to $5.0. The market value of their outstanding shares is at $112.8 million. </li>
<li>Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) stock fell 15.26% to $5.11. The company's market cap stands at $43.7 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock decreased by 13.62% to $1.65. The market value of their outstanding shares is at $25.0 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares declined by 12.46% to $0.05. The market value of their outstanding shares is at $1.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ENSC

FBRX

GELS

GLYC

INTS

NDRA

NTHI

PTPI

RZLT

SNOA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Shares of Levi Strauss &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) rose sharply in today's pre-market trading after reported better-than-expected earnings for its <a href="https://in.benzinga.com/news/earnings/25/04/44674732/levi-strauss-shares-rise-after-mixed-q1-results-details">first quarter on Monday</a>.
Levi Strauss &amp; Co. reported quarterly adjusted earnings of 38 cents per share, which beat the 28 cent analyst consensus estimate.
Levi also said its 2025 guidance remains unchanged, other than to reflect its Dockers business as a discontinued operation, and does not reflect any impact from the recently announced tariffs.
Levi Strauss shares jumped 10.7% to $14.94 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>SaverOne 2014 Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) rose 110.1% to $6.81 in pre-market trading after gaining 22% on Monday.</li>
<li>Galaxy Payroll Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) rose 106.5% to $1.94 in pre-market trading after gaining around 24% on Monday.</li>
<li>P10, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) rose 39% to $13.80 in pre-market trading after gaining 5% on Monday.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) surged 38.4% to $6.77 in pre-market trading.</li>
<li>American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) gained 27.1% to $13.49 in pre-market. American Rebel Holdings, on Monday, issued an update highlighting recent milestones and strategic growth initiatives including successful private placement by H.C Wainwright and media push in South Florida.</li>
<li>MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) rose 24.4% to $23.00 in pre-market trading.</li>
<li>Pursuit Attractions and Hospitality, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRSU#NYSE">PRSU</a>) gained 20.7% to $36.99 in pre-market trading.</li>
<li>Iveda Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) rose 20.6% to $2.81 in pre-market trading.</li>
<li>Unifi, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) gained 18.8% to $5.30 in pre-market trading after falling 5% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) fell 50.5% to $2.00 in pre-market trading after gaining around 5% on Monday.</li>
<li>Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares tumbled 45.7% to $4.07 in pre-market trading after the company announced entry into warrant inducement transaction for approximately $3.7 million in gross proceeds.</li>
<li>CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) fell 29.8% to $8.10 in today's pre-market trading after the company reported preliminary first quarter 2025 financial results.</li>
<li>KNOT Offshore Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNOP#NYSE">KNOP</a>) shares dipped 25.3% to $4.60 in pre-market trading after falling over 4% on Monday.</li>
<li>Shattuck Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) fell 23.8% to $0.9902 in pre-market trading after jumping 77% on Monday.</li>
<li>Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares fell 23.4% to $0.3186 in pre-market trading after surging 90% on Monday.</li>
<li>Graphex Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#NYSE">GRFX</a>) shares fell 19.2% to $0.9210 in pre-market trading following a 7% gain on Monday.</li>
<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) fell 18.8% to $1.08 in pre-market trading after tumbling 30% on Monday.</li>
<li>Collective Mining Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNL#NYSE">CNL</a>) declined 12.2% to $7.31 in pre-market trading.</li>
<li>The Greenbrier Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) dipped 3.9% to $43.00 in pre-market trading as the company posted downbeat results for its second quarter.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44678097/walgreens-rpm-international-and-3-stocks-to-watch-heading-into-tuesday">Walgreens, RPM International And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

News

Pre-Market Outlook

Markets

AREB

BJDX

CHSN

CVRX

GLXG

GRFX

IPDN

IVDA

KNOP

LEVI

PRSU

SOBR

STTK

SVRE

Why Levi Strauss Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and lowers the price target from $75 to $54.

Price Target

Analyst Ratings

Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $54

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

HC Wainwright &amp; Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and raises the price target from $7 to $56.

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $56

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

General

Karyopharm Therapeutics shares are trading lower after the company announced a 1-for-15 reverse stock split.

Karyopharm Announces 1-for-15 Reverse Stock Split, Effective February 25, 2025

RBC Capital analyst Brian Abrahams reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and maintains $3 price target.

Reiteration

RBC Capital Reiterates Outperform on Karyopharm Therapeutics, Maintains $3 Price Target

HC Wainwright &amp; Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and maintains $7 price target.

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target

Biotech

Health Care

Karyopharm Says Phase 3 XPORT-EC-042 Trial Of Selinexor As Maintenance Therapy In Advanced or Recurrent TP53 Wild-Type Endometrial Cancer To Focus Enrollment Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkpoint Inhibitors. Increasing Sample Size to 276, Top-Line Data Now Expected in Mid-2026

<ul>
<li>The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO net product sales, as well as revenue generated from its license agreements, will be sufficient to fund its planned operations into the first quarter of 2026.</li>
</ul>

Guidance

Karyopharm Expects 2025 Sales Of $140M-$155M Versus Consensus Of $160.55M, With US Xpovio Net Product Revenue Expected To Be $115M-$130M

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 33.33 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $30.54 million which missed the analyst consensus estimate of $34.86 million by 12.40 percent. This is a 9.50 percent decrease over sales of $33.75 million the same period last year.

Karyopharm Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.26) Estimate, Sales $30.54M Miss $34.86M Estimate

ACVA

AMPL

ANSS

APPN

BLCO

BMRN

BORR

CAKE

CCAP

CCSI

CHDN

CLVT

CMTG

CVNA

CWAN

ENLT

ENVX

ESRT

ETSY

EXAS

FOLD

First Trust Advantage Preferred Income Fund

FVRR

GLBE

GRAB

GRMN

HSBC

ICLR

IIPR

IMAX

INSG

IONS

KALU

KRYS

KVYO

LILA

LILAK

LOPE

LUNG

MANU

MATV

MGRC

MTRN

NDSN

NRDS

NYMT

OBDC

PAAS

PERI

PNST

PRAA

Earnings Scheduled For February 19, 2025

– Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company On Track to Complete Enrollment in 1H 2025 –&nbsp;
– Recently Announced Key Leadership Changes, including the Appointment of Lori Macomber as Chief Financial Officer and Brendan Strong as SVP of Investor Relations and Corporate Communications –&nbsp;
– Preliminary Unaudited Full Year 2024 Total Revenue and U.S. XPOVIO&#xAE;&nbsp;(selinexor) Net Product Revenue Expected to be Approximately $145 Million and $113 Million, Respectively –
NEWTON, Mass., Jan. 13, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2024 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2024 achievements and 2025 objectives.

Management

Karyopharm Therapeutics Announces Phase 3 SENTRY Trial Data For Selinexor In JAKi-Naïve Myelofibrosis Expected In H2 2025; Enrollment By H1 2025; Lori Macomber Appointed Chief Financial Officer; Preliminary 2024 Revenue At $145M And XPOVIO Sales Reached $113M

Comments

Karyopharm Therapeutics

Notizie

Ultime notizie per Karyopharm Therapeutics (NASDAQ:KPTI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO